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Ribozymes are a class of RNA molecules that can per­
form catalytically in the absence of protein. Specifi­
cally, they can hybridize to and cleave target RNA 
molecul�s independent of cellular proteins. ;rhe 
cleaved target RNA can not be translated thereby pre­
venting synthesis of a specific protein. The therapeutic 
application is to target the ribozyme to the mRNA of a 
key protein or proteins involved in maintaining a dis­
ease state resulting in a cure. The ribozymes can be 
chemically synthesized and delivered to cells or they 
R 
ibozymes are RNA molecules that hybridize to a com­
plementary sequence of RNA and cleave that se­
quence in the absence of proteins. The ribozyme is 
composed of two domains, a binding domain and an 
RNA cleaving domain. The ribozyme hybridizes to 
the target RNA via Watson-Crick base pairing resulting in the 
orientation of the cleavage sequence within the target RNA to be 
acted upon by the catalytic domain of the ribozyme. Only then is 
the ribozyme able to cleave the target RNA. The ribozyme also 
requires divalent cation for cleavage. Mter cleavage of the target 
RNA, the cleavage products dissociate from the ribozyme making it 
available to hybridize to another sequence. 
Development of this technology into a therapy requires the fol­
lowing: i) identification of a key protein responsible for a disease 
state, ii) the nucleotide sequence for that protein must be known to 
select the ribozyme cleavage sites, iii} the ribozyme must cleave the 
target RNA, and iv) the ribozyme must be taken up by the cells of 
the diseased tissue and cleave the target RNA inside the cell. 
Several examples exist in the literature using ribozymes to pre­
vent specific proteins from being synthesized. These ribozymes 
were either expressed from an expression vector or formulated in a 
delivery vehicle to facilitate cellular uptake. An active area of appli­
cations has been in the development of AIDS theapeutics [1-4]. 
Ribozymes have been designed to cleave the RNA coding for the 
gag protein [5] the 5' leader sequence in the LTR [6] and the pro­
tease [7]. The most effective application consists of a hairpin ribo­
zyme directed against the 5' leader sequence [8,9]. The ribozyme 
was incorporated into a retroviral vector and transfected into Jurkat 
cells and shown to protect these cells against HIV infection using 
the HIV IIIb strain. This vector was then shown to transform pri­
mary immune cells and protect those cells from infection by several 
different strains ofHIV-I including two clinical isolates [9]. These 
results spurred the preparation and submission of a human gene 
therapy protocol for the treatment ofHIV. This protocol has been 
approved for phase I clinical safety trials. 
There have been two reported applications in the area of cancer. 
The first involves inhibition of cell proliferation by a ribozyme 
Reprint requests to: Sean M. Sullivan, Ribozyme Pharmaceuticals, Inc., 
2950 Wilderness Way, Boulder, CO 80301. 
can be expressed from an expression vector following 
either permanent or transient transfection. Therapeu­
tic applications of ribozymes have been in the areas of 
AIDS and cancer. The following article describes the 
ribozymes in more detail with respect to optimizing 
the design to obtain the maximal cleavage rate, identi­
fying cleavage sites within the target RNA and deliv­
ering the ribozymes to cells ofinterest both in vitro and 
in vivo.] Invest Dermatol10J:8SS-89S, 1994 
directed against the ,as oncogene [10-12]. There is a point muta­
tion in the ,as oncogene converting a GUG nucleotide sequence to a 
GUC. The GUG triplet can not be cleaved by a hammerhead ribo­
zyme whereas the GUC triplet can be cleaved. The ribozyme re­
duced the amount of mRNA from the ,as oncogene and inhibited 
cell proliferation. The second example involves the treatment of 
Chronic Myelogenous Leukemia (CML) [13,14]. In the first stage 
oflymphocyte transformation, there is a translocation of c-abl from 
chromosome 9 to the break point cluster region of chromosome 22 
resulting in the formation of a bcr-abl fusion protein. A ribozyme 
cleavage site is created at the junction of these two proteins. A 
ribozyme was designed so that one binding arm hybridized to the ber 
side and the other binding arm of the ribozyme hbyridized to the abl 
side of the mRNA, such that only the mRNA of the fusion product 
would be cleaved and not the RNA from either ber or abl. A chemi­
cally synthesized ribozyme composed of both DNA and RNA was 
introduced into these cells by cationic lipids. The results showed 
that the ribozyme reduced the amount of the fusion protein and the 
fusion protein mRNA, and cell proliferation was inhibited. How­
ever, there was no effect on the amount of c-abl protein, thus dem­
onstrating the specificity of the ribozyme [13]. A similar result was 
observed expressing the ribozyme from a retroviral vector [14]. The 
design of the ribozyme was similar to the chemically synthesized 
ribozyme and inhibition of cell proliferation was observed. 
Application of this technology is not only limited to human ther­
apeutics, but to other areas, such as agriculture. Specifically, a ribo­
zyme was directed against the tobacco mosaic virus (TMV) RNA­
dependent RNA polymerase, a crucial protein for replication. The 
ribozyme was expressed from a transient expression vector trans­
fected into tobacco plant protoplasts. Ribozyme activity was com­
pared to an antisense construct to the same area as the ribozyme 
sequence. The antisense COnstruct reduced virus production by 20% 
whereas the ribozyme inhibited virus production by 90% [38 J. This 
ribozyme construct was used to generate transgenic plants and 
shown to have retardation in symptom development as the result of 
TMV infection. 
These examples show that to develop an effective ribozyme based 
therapy requires the identification of a key protein, which in tum 
rt:9.uires knowledge of the mechanism for the disease. The design of 
effective ribozymes to cleave the mRNA of this protein is 
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absolutely paramount to achieving a ribozyme-based therapy. The 
following describes in more detail how ribozymes work and how 
they can be optimized to be effective therapeutics. 
RIBOZYME CHARACTERISTICS 
There are five type of ribozyme motifs: group I introns, ribonucle­
ase P, hammerhead, hairpin and hepatitis delta virus ribozymes. The 
group I intron motif was discovered by Dr. Tom Cech and col­
leagues at the University of Colorado in Boulder. The natural role 
of this ribozyme is to process ribosomal RNA. Splicing of the rRNA 
intron occurs by a two step mechanism. In the first step, guanine 
nucleotide is added to the 5' end of the intron as the intron/exon 
junction is being cleaved. In the second step, the freed 5' exon 
attacks at the 3' intron/ exon junction to release the intron and to 
generate a spliced exon [15,6]' Ribonuclease P was discovered in 
bacteria by Dr. Sydney Altman and colleagues. The ribozyme is 
composed of a small subunit protein and a catalytic RNA. The 
biologic role is to generate the mature 5' -end of tRNAs by endonu­
cleocatalytic cleavage of precursor transcripts [17]. Dr. Robert 
Symons and colleagues at the CSIRO in Australia described the 
hammerhead motif in viroids, which are helper viruses found in 
plants. The RNA is synthesized in a rolling circle and the hammer­
head, upon hybridization, cleaves the polycistronic message into 
individual RNA transcripts [18] . The hairpin ribozyme was discov­
ered by Dr. George Bruening and colleagues at the University of 
California, Davis [19]. The role of the hairpin is also found in plant 
viroids and has a similar role as the hammerhead [20,21]. The hepa­
titis delta virus is a helper virus and its RNA was found to have 
autocatalytic RNA processing similar to the function of the hairpin 
and hammerhead mo�ifs [22]. The details of this ribozyme motif are 
still being characterized with respect to minimal sequence and sub­
strate requirements. 
HAMMERHEAD RIBOZYME DESIGN 
The hammerhead ribozyme was selected for development as a ther­
apeutic for several reasons. It is the smallest of the ribozyme motifs 
and is therefore appealing for chemical synthesis. It has been the best 
characterized ribozyme with respect to optimized target sequence, 
conserved nucleotides sequences within the catalytic core, and the 
kinetic parameters. In addition, the target RNA cleavage sites have 
the least constraints with respect to sequence and therefore are the 
most abundant sites compared to the other motifs. Figure 1 depicts 
the formed hammerhead motif from bound ribozyme and substrate. 
The non-base paired nucleotides flanking both sides of stem II make 
up the catalytic core. These sequences are the CUGAUGA on the 5' 
side of stem II and the GAAA on the 3' side of stem II. Stem II can 
vary in sequence and length. The combination of a high GC content 
in the stem and the GAAA tetra loop stabilizes this structure. 
The substrate and the ribozyme hybridize to form stem I and stem 
III, orienting the -UH- nucleotides of the substrate over the cata­
lytic core. The H nucleotide can be an adenine, cytosine or uridine 
but not a guanine. Ruffner and Uhlenbeck [23] identified aGUe 
nucleotide triplet to yield the highest rate o( cleavage compared to 
the other cleavage triplet sequences. However, it has been our expe­
rience that the optimal triplet is dependent upon the ribozyme 
binding arm composition and the nucleotide composition of the 
target RNA. 
The proposed mechanism of a hammerhead mediated RNA 
cleavage begins with deprotonation of the 2' sugar at the 3' side of 
the cleavage site. Deprotonation results in nucleophilic attack of the 
adjacent phosphodiester bond and subsequently protonation of the 
5' oxyanion leaving group generating 2' ,3' -cyclic phosphate and 5' 
hydroxyl termini. The 2' hydroxyl adjacent to the cleavage site in 
the substrate is essential for cleavage . The rates of ribozyme hybrid­
ization to the substrate, dissociation of the ribozyme from the sub­
strate, and dissociation of the cleavage products from the ribozyme 
are controlled by the length and nucleotide composition of the 
binding arms. Hence, the dependence of binding arm lengths on the 
cleavage rate should be determined for each ribozyme of interest. 
The arm lengths can be optimized using either short target sub-
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Figure 1. Structure of the hammerhead ribOZYllle. The hammerhead 
ribozyme is in bold. Stem 1 and stem II are the binding arms and stem II is part 
of the catalytic core. The !! represents the cleavage site of the substrate 
RNA. 
strates (:520 nucleotides) or long substrates (2:500 nucleotides). 
However, optimization should also be coordinated with a biologic 
assay because the ultimate test is the inactivation of an RNA tran­
script inside the cell. Optimization of the arm lengths of an ex­
pressed ribozyme should be performed in the context of the expres­
sion vector, which would involve extracting the RNA from the 
transfected cell and assaying for cleavage in the presence of other 
cellular RNAs. 
NUCLEASE STABILITY 
Ribozymes are composed of RNA and are therefore susceptible to 
degradative enzymes inside and outside the cell. Development of a 
ribozyme that is resistant to these degradative nucleases should in­
crease the rate of ribozyme accumulation in the cell, thereby de­
creasing the effective dose required for inhibition of protein synthe­
sis . Chemical modification of the phosphate backbone and 
derivatization of the 2' -OH of the ribose have been strategies to 
achieve this goal. The phosphodiester backbone was changed to a 
phosphorothioate and modifications to the 2'-OH of the ribose 
have included 2'-fluoro [24], 2'-amino [24] , 2'-O-methyl [25], 2'­
O-allyl [26] and 2'-deoxy [27,28]. Some of the modifications re­
duced the cleavage rate of the ribozyme and, therefore, there must 
be a balance between increasing the nuclease stability and decreasing 
the ribozyme cleavage activity. Reduction in cleavage activity was 
�ependent upon the nature of the modification and the site of inser­
"rion in the hammerhead ribozyme. A ribozyme containing three 
terminal phosphorothioates at the 3' end and one terminal phos­
phorothioate at the 5' end along with 2'-fluoro-2' -deoxyuridines 
and two 2' -amino-2' -deoxyuridines increased the tt/z from less than 
1 min to 3 h in serum with a 40% loss in cleavage activity [2,241. 
The development of a synthetic ribozyme resistant to nuclease deg­
radation is a key factor in making this technology a viable parenteral 
administered pharmaceutical. 
Ribozymes expressed from a DNA vector can be engineered to 
increase intracellular stability. This is accomplished by creating sec­
ondary structures within the RNA that inhibit nuclease degrada­
tion. Stem-loops are one type of structure and are formed by intra­
strand base pairs. Placement of stem loops on either side of a 
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ribozyme was shown to slow the rate of ribozyme degradation and 
produced a greater reduction in the amount of a specific protein 
compared to a ribozyme lacking these structures [29). Exonuclease 
degradation is initiated at either the 3' end or the 5' end of the RNA. 
Circularizing the RNA would make these ends inaccessible to the 
exonuclease. The effect of circular RNA on reducing nuclease deg­
radation was tested using the hepatitis delta virus ribozyme motif. 
The ribozyme was expressed in such a way that processing of the 
transcript yielded a circular ribozyme [30). The circularized ribo­
zyme was shown to retain catalytic activity and serum nuclease 
degradation was dramatically reduced. This is a promising approach 
that is being evaluated for ribozyme activity inside cells. 
RIBOZYME SELECTION 
The rate of cleavage of a target RNA is dependent upon the accessi­
bility of the cleavage site. Hammerhead ribozyme cleavage sites are 
selected by first identifying the U-H doublets in the nucleotide 
sequence of the target RNA with U being uridine and H being a 
cytosine, uridine, or adenine but not a guanine. The next round of 
selection is based on the degree of homology between the animal 
and human sequences or in the case of HIV, the most conserved 
sequences between the different strains of virus. The ribozyme is 
then folded with the corresponding sequence using a computer 
folding program. Only, those sites that yield a successful ribozyme 
motif are then tested for accessibility. Site accessibility is assayed 
using a combination of deoxyoligonucleotides and RNase H with in 
vitro transcripts. The deoxyoligonucleotides are hybridized to the in 
vitro transcripts in vast excess of RNase H. The enzyme degrades 
RNA from the DNA/RNA heteroduplex. The minimum length 
for the deoxyoligonucleotides has been 13 nucleotides and the ribo­
zyme cleavage site is placed in the middle of the oligonucleotide. 
The RNA transcripts are uniformly labeled with 32p nucleotides and 
the intact transcript and the two cleavage products are visualized on 
the gel by autoradiography. A data base has been established to 
correlate the accessibility results with the predicted RNA structure 
using a computer folding program. The validation of the computer 
fold of the RNA transcript to select ribozyme cleavage sites is in 
progress. The establishment of this data base should expedite the 
ribozyme development process. 
Ribozymes to the identified accessible sites are synthesized and 
assayed for activity. The most active ribozymes are then assayed for 
activity in tissue culture. 
RIBOZYME DELIVERY 
Three options exist for ribozyme delivery: uptake of synthetic ribo­
zymes, expression from a transient expression vector, or expression 
from an integrated vector. Each delivery option has its own applica­
tion. Synthetic ribozymes behave very similar to conventional drugs 
in that they are applicable to diseases that require multiple adminis­
tr.Itions. The additional advantage being a defined mechanism of 
action and lack of cytotoxic side effects. 
Synthetic ribozymes are taken up by cells, but the uptake effi­
ciency is low. This efficiency can be increased through the use of 
dtlivery vehicles. Cationic lipids have been successful in facilitating 
delivery of the transient expression vectors [31], messenger RNA 
\321, and antisense DNA [33] to cells both in vitro and in vivo [34]. 
They are also able to facilitate ribozyme delivery (unpublished re­
sults). The cationic lipids are commercially available and the proto­
col is very simple. The ribozyme is added to the cationic liposomes 
and a complex forms spontaneously. The ribozyme/cationic lipid 
complex is then added to the cells. For in vitro use, there are two 
restrictions. These lipids are toxic to the cells and a toxicity profile 
of the cationic lipid/ ribozyme complex must be established prior to 
dlicacy studies. Secondly, the cells must be in a serum free environ­
ment during incubation with the complex. A 2 - 4 h incubation is 
su8icient for ribozyme uptake. For a more detailed discussion of 
oprimizing activity and minimizing toxicity, see Felgner et at [35]' 
For cells that cannot tolerate the cationic lipid or lack of serum, 
phospholipid liposomes have been used for ribozyme delivery. Li­
pOJOmcs are hollow spheres composed of phospholipids arranged in 
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a bilayer configuration and the ribozymes are trapped inside the 
liposomes. For a description of phospholipid liposome preparation 
see Sullivan, 1993 [36]. The liposomes rely on endocytosis to gain 
entry into the eel!. Upon entry, they are de graded and the ribozymes 
are released into the cytoplasm. Uptake and release from endocytic 
vacuoles are dependent upon cell type and phospholipid composi­
tion. This is particularly true for cytoplasmic release of liposome 
contents. Release is dependent upon the lipid degradative enzymes 
in the endosome and lysosome. For example, a liposome formula­
tion composed of phosphatidylethanolamine, phosphatidylcholine, 
and cholesterol was actively taken up by vero cells yielding 70% of 
the ribozymes in the cytoplasm. The same formulation was tested 
for uptake by HeLa cells showing that less than 5% of the offered 
dose was taken up and the ribozymes were sequestered inside intra­
cellular vacuoles. The present state of the art requires that the lipid 
composition be designed for the cell type of interest and both uptake 
and intracellular release of the ribozyme must be taken into account. 
In vivo delivery of synthetic ribozymes was achieved for topical 
delivery using polyacrylic acid, a controlled release polymer. The 
properties of the polyacrylic acid are that upon hydration, the po­
lyacrylic acid is a liquid at pH 5. Neutralization with a weak base 
converts the solution to a gel. Penetration of the gel by cations 
collapses the gel back to a liquid. The ribozymes were formulated 
with polyacrylic acid and applied to mouse eyes as a liquid. An 
83 pmol dose was applied and 5% was retained by the eye. The 
percent of ribozyme retained by the eye was linear over the range of 
83 pmol to 1660 pmo!. Autoradiography op3P-radiolabeled ribo­
zyme showed localization of the ribozyme in the outer most layers 
of the corneal epithelium after 10 min. After 30 min the ribozyme 
had penetrated into the lower area of the epithelium layer and into 
the stromal layer . This study showed that synthetic ribozymes could 
be maintained at a level within tissue from a local administration. 
These results may be more generally applicable to other topical 
administration routes. 
Ribozyme expression from an expression vector falls under the 
category of gene therapy. Delivery and expression of a ribozyme 
expression vector presently relies upon the use of non-replicating 
viruses, such as retrovirus, adenovirus or adeno-associated virus. 
Retroviruses and adeno-associated viruses result in stable trans fec­
tants whereas infection with adenovirus' results in transient trans­
fectants. Hence, infection with retroviruses and adeno-associated 
viruses yields permanent transfections that have the potential for 
continuous ribozyme expression and adenovirus produces a tran­
sient transfection that yields transient ribozyme expression. Safety 
issues surrounding the integration of foreign DNA derived from a 
virus are still being addressed and for this reason ribozyme gene 
therapy may be used for limited applications. For example, transient 
expression of ribozymes may be applicable to non-life threatening 
acute diseases, such as restenosis, where multiple administrations 
cannot be tolerated. Ribozyme expression from an integrated vector 
may be applicable to life threatening chronic diseases, such as AIDS, 
where multiple administrations can not be tolerated. 
Vector transfection for transient expression can take two forms. 
The first is to use adenoviral vectors as a means for ribozyme to be 
introduced into the cells and expressed. The advantages of adenovi­
rus are a high transfection efficiency, a therapeutic level of protein 
expression, and high titers from packaging cell lines [39]. Expres­
sion of proteins has been maintained for 1 - 3 weeks after in vivo 
transfection. A disadvantage of adenovirus vectors involves the po­
tential of recombination between replication and replication com­
petent vectors. Another concern is the immunogenicity of this virus 
creating immune based inflammation problems [40). 
The second form is non-viral mediated DNA vector transfection, 
which alleviates these problems by using double stranded DNA 
alone to express the ribozyme. Direct DNA injection into skeletal 
muscle has been used in vaccine approaches for antigen expression. 
However, for other tissues, transfection efficiencies are greatly in­
creased using cationic lipid/DNA complexes. Cationic lipid me­
diated DNA transfection yields a high transfection efficiency both 
in vitro and in vivo [34,35]. A Phase I clinical trial for the treatment of 
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melanomas has been completed using cationic lipids to deliver plas­
mid DNA. DNA encoding a foreign major histocompatibility anti­
gen was complexed with cationic lipids and injected directly into 
the tumor. The patients' immune system recognizing the foreign 
antigen eliminated the tumors. Other protocols for this type of gene 
expression are in the review process for human clinical trials. 
Permanent transfection is achieved with viral vectors that inte­
grate into host DNA. The most widely used vector for these pur­
poses has been the retroviral vectors [41-43]. As is the case for 
adenovirus, retroviral vector delivery uses replication incompetent 
viruses. The replication incompetent virions are produced by a 
packaging cell line transfected with the retrovirus genes necessary 
for virion production but lacking the If! packaging sequence neces­
sary for packing the viral genome into the vition. The ribozyme is 
cloned into a retroviral vector that contains only the long terminal 
repeats (LTRs) responsible for host DNA integration of the viral 
genome. The packaging cells produces virion particles that contain 
all the machinery for infection and replication but lack the viral 
genome. In its place is the ribozyme genome flanked by the L TRs 
and also containing a selectable marker gene to enrich for the trans­
fected cell. These virions are then used to infect the target cell. Cells 
must be dividing for retroviral integration to occur. Retroviruses 
have a reasonable transfection efficiency, averaging 10%. Transfec­
tion is often performed ex vivo followed by selection of the perma­
nently transformed cells. The cells are then returned to the patient. 
If the transfection frequency is reasonably high, cells may be re­
turned to patients without selection. The disadvantages of retroviral 
vectors are low titers (between lOS and 106 PFUs/ml) and random 
integration into the host DNA. 
Another vector under consideration is adeno-associated virus 
[44]. This expression vector is propagated in the same manner as the 
retroviral vectors, however, a helper virus such as adenovirus or one 
of the herpes viruses is also required. This vector offers the follow­
ing advantages. i) The packaging cell lines produce similar titers to 
that of the retroviruses; however, unlike retroviruses, the adeno-as­
sociated virus can be concentrated. ii) Integration is specific for 
unmodified virus at human chromosome 19 and the only sequences 
required for integration are the flanking LTRs [45]. iii) Integration 
does not require that the target cells be dividing. This vector has just 
entered the gene therapy arena and extensive studies on long term 
expression, site specific integration, and potential activation by 
helper viruses are in progress. 
Vectors applicable to ribozyme expression have been designed for 
protein expression, not RNA expression. For this reason, direct 
application of existing protein expression systems toward ribozyme 
delivery may not be straightforward. In all likelihood, the ribozyme 
may require a custom designed expression cassette to maximize the 
level of expression. In designing this vector system, several consid­
erations must be taken into account. 
In order for the ribozyme to be effective, it must either be in 
excess of the target RNA or colocalize with the target to increase the 
effective concentration [37]. If the ribozyme is transcribed from the 
same RNA polymerase as the target RNA, i.e., RNA polymerase II, 
the ribozyme promoter must be a stronger promoter than the target 
RNA, there must be multiple copies of the ribozyme expression 
cassette, or multiple ribozymes must be expressed under a single 
promoter. Ribozyme cleavage requires that the ribozyme form the 
hammerhead structure and the presence of additional ribozymes has 
the potential of yielding non-productive folding of the RNA. In­
corporation of self processing ribozymes flanking either side of the 
therapeutic ribozymes would eliminate this possibility. The feasi­
bility of this latter approach has been demonstrated [3]. 
An alternative would be to express the ribozyme under another 
promoter that had a higher transcription rate. Endogenous RNAs, 
such as snRNA and tRNA are transcribed by RNA Polymerase III, 
and ribosomal RNA is transcribed by RNA polymerase I. The en­
dogenous RNA promoters are of interest because the abundance of 
these RNAs is greater than anyone species of mRNA. A hairpin 
ribozyme shown to be effective against HIV was expressed from an 
RNA polymerase III tRNA promoter [9]. The transcription unit 
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bearing the ribozyme was inserted into a retroviral vector and this 
vector was used to transfect primary human lymphocytes. 
All ribozyme expression to date has been in in vitro systems. The 
approved protocol for HIV human gene therapy will be the first in 
vivo study. The goal of the protocol is a safety trial for the retroviral 
ribozyme expression vector. From these studies will also emerge 
preliminary results concerning the duration and expression level of 
ribozymes in human T cells in vivo. Second generation protocols 
will involve the transfection of human stem cells followed by auto­
logous bone marrow transplantation. This approach will expand the 
number and types of immune cells capable of expressing the ribo­
zyme. 
There is a great promise in ribozyme technology because of the 
wide application toward the treatment of disease and medical disor­
ders. Unlike the small molecule drugs that are effective in curing 
disease but often suffer from non-specific toxic side effects, ribo­
zymes have exquisite specificity thus avoiding the toxic side effects. 
Ribozymes have the option of being delivered as a synthetic RNA or 
they can be expressed from an expression vector. The main limita­
tion to this technology is the proper identification of a protein 
responsible for the disease state. In view of the rapid pace molecular 
cell biology is moving along with the progression of the human 
genome project, the significance of this limitation should be greatly 
reduced. 
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